Research summaries for everyoneNot medical advice
TB-500 research reference vial, Elevated Pharma

Research reference · Tissue Repair

TB-500

FDA defines TB-500 as the seven-residue thymosin beta-4 fragment LKKTETQ with N-terminal acetylation. It is not full-length thymosin beta-4, and most published research is on the full-length protein.

Published by Elevated Pharma ·

Tissue RepairIdentity review required

Identity

What is TB-500?

N-acetyl-LKKTETQ, a fragment of thymosin beta-4 (residues 17–23).

Research context

What has TB-500 been studied for?

Human trials studied full-length thymosin beta-4 (for example in venous ulcers). FDA reported finding no published in-vivo wound studies for the defined fragment itself.

Evidence boundary

What does the research not show?

Full-length thymosin beta-4 evidence cannot be assigned to TB-500 without exact structural documentation.

U.S. status · November 7, 2026

Is TB-500 FDA-approved?

FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 23, 2026 (vote 8–6, one abstention; the nominated substance was the fragment). On October 28, 2026, HHS issued an interim policy saying it will not take enforcement action against licensed pharmacies and physicians that compound it under listed conditions, such as FDA-registered sourcing, a certificate of analysis and safety reporting. It is not FDA-approved, and the policy does not cover research-use-only material.

Research updates

What’s new

Dated developments for TB-500, newest first. See all research updates.

  1. HHS interim compounding policy

    HHS published an enforcement-discretion policy covering BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 for licensed pharmacies and physicians. Comments close November 13, 2026.

    Read the source
  2. Orthopaedic review

    A JAAOS review of BPC-157, thymosin beta-4 and TB-500 finds mostly preclinical evidence.

    Read the source
  3. FDA advisory committee votes

    FDA’s Pharmacy Compounding Advisory Committee voted on seven peptides over July 23–24, recommending six and declining emideltide (DSIP).

    Read the source

Key studies

The main TB-500 research

Selected from PubMed: human trials first, then reviews, then foundational laboratory work. Each finding applies to the material and setting studied.

Search all 629 PubMed records for TB-500 · Counts and selections checked November 7, 2026.

Reference identifiers

TB-500 identity data

Database identity describes the reference substance, not any specific material or lot.

Primary name
TB-500
Also indexed as
N-acetyl-LKKTETQ / Thymosin beta-4 fragment 17-23
Sequence
N-acetyl-LKKTETQ

Official & primary sources

Regulatory and database records

Citation does not imply an Elevated Pharma partnership or endorsement.